This summary was created by AI, based on 1 opinions in the last 12 months.
The experts' reviews on Catalent (CTLT-N) are generally negative, with one reviewer mentioning a past financial problem and advising to stay away from the stock for a while. This indicates potential instability and risk associated with investing in this company. Investors may want to proceed with caution and conduct further research before considering this stock for investment.
Danaher (he owns) or Illumina could buy CTLT, at least that's the talk. Until something happens, he won't buy this.
They make the tools that helped Moderna make the Covid vaccine. Roared during the pandemic, then crashed in 2022, but is soaring now. Rumoured that Danaher could take this over.
Catalent is a American stock, trading under the symbol CTLT-N on the New York Stock Exchange (CTLT). It is usually referred to as NYSE:CTLT or CTLT-N
In the last year, 1 stock analyst published opinions about CTLT-N. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Catalent.
Catalent was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Catalent.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Catalent published on Stockchase.
On 2024-10-11, Catalent (CTLT-N) stock closed at a price of $60.45.
They had a financial problem. Stay away for a while.